FIELD: pharmacology.
SUBSTANCE: invention concerns biotechnology, specifically to oligomer compound of length 10-30 nucleic bases, and can be used in medicine. The oligomer compound represents a target-binding domain complementary to a segment of 10-18 sequential nucleotides of the region including base position 1459 (5') to 1476 (3') human mRNA Bcl-2 (HUMBcl2A (approach number M13994) in database GenBank), except maximum one inaccurate coupling with specified site of human mRNA Bcl-2 where said target-binding domain is described by formula: 5' - [(DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3'.
EFFECT: oligomer compound effectively reducing expression of human gene Bcl-2.
25 cl, 20 dwg, 3 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
| FACTOR 11 EXPRESSION MODULATION | 2009 |
|
RU2535964C2 |
| MODULATION OF FACTOR 11 EXPRESSION | 2014 |
|
RU2739594C2 |
| MODULATION OF ANDROGEN RECEPTOR EXPRESSION | 2013 |
|
RU2670486C9 |
| TREATMENT OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO BDNF | 2013 |
|
RU2661104C2 |
| OLIGONUCLEOTIDE CONJUGATES | 2013 |
|
RU2653438C2 |
| TREATING SIRTIUN 1 (SIRT1)-RELATED DISEASES BY INHIBITON OF NATURAL ANTISENSE TRANSCRIPT | 2009 |
|
RU2551234C2 |
| TREATMENT OF DISEASES ASSOCIATED WITH ERYTHROPOIETIN (EPO) BY NATURAL EPO ANTISENSE TRANSCRIPT INHIBITION | 2009 |
|
RU2620970C2 |
| METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS, DIRECTLY ACTING ON CONNECTIVE TISSUE GROWTH FACTOR (CTGF) | 2012 |
|
RU2608655C2 |
| TREATMENT OF APOLIPOPROTEIN-A1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO APOLIPOPROTEIN-A1 | 2009 |
|
RU2604489C2 |
